TY - JOUR
T1 - NF1 truncating mutations associated to aggressive clinical phenotype with elephantiasis neuromatosa and solid malignancies
AU - Ponti, Giovanni
AU - Martorana, Davide
AU - Pellacani, Giovanni
AU - Ruini, Cristel
AU - Loschi, Pietro
AU - Baccarani, Alessio
AU - De Santis, Giorgio
AU - Pollio, Annamaria
AU - Neri, Tauro Maria
AU - Mandel, Victor Desmond
AU - Maiorana, Antonio
AU - Maccio, Livia
AU - Maccaferri, Monia
AU - Tomasi, Aldo
PY - 2014/6/1
Y1 - 2014/6/1
N2 - Background/Aim: Von Recklinghausen disease is a syndrome characterized by a wide phenotypic variability giving rise to both, cutaneous and visceral benign and malignant neoplasms. The first include cutaneous neurofibromas, subcutaneous and plexiform neurofibromas. The latter can undergo malignant transformation and/or determine elephantiasis neuromatosa. Visceral tumors may include malignant peripheral nerve sheet tumors, gastrointestinal stromal tumors, cerebral gliomas and abdominal neurofibromas. In the present study, the authors discuss the clinical and biomolecular characterization of a cohort of 20 families with a diagnosis of type 1 neurofibromatosis. Patients and Methods: Clinically, the cohort includes three probands with elephantiasis neuromatosa and a peculiarly high incidence of breast and gastrointestinal cancer. Results: Among the 14 NF1 mutations documented, 10 encoding for a truncated protein have been associated to particularly aggressive clinical phenotypes including elephantiasis neuromatosa, malignant peripheral nerve sheet tumors, breast cancer, gastrointestinal stromal tumors. Conclusion: This effect on protein synthesis, rather than the type of NF1 mutation, is the key to the explanation of the genotype-phenotype correlations in the context of neurofibromatosis type 1.
AB - Background/Aim: Von Recklinghausen disease is a syndrome characterized by a wide phenotypic variability giving rise to both, cutaneous and visceral benign and malignant neoplasms. The first include cutaneous neurofibromas, subcutaneous and plexiform neurofibromas. The latter can undergo malignant transformation and/or determine elephantiasis neuromatosa. Visceral tumors may include malignant peripheral nerve sheet tumors, gastrointestinal stromal tumors, cerebral gliomas and abdominal neurofibromas. In the present study, the authors discuss the clinical and biomolecular characterization of a cohort of 20 families with a diagnosis of type 1 neurofibromatosis. Patients and Methods: Clinically, the cohort includes three probands with elephantiasis neuromatosa and a peculiarly high incidence of breast and gastrointestinal cancer. Results: Among the 14 NF1 mutations documented, 10 encoding for a truncated protein have been associated to particularly aggressive clinical phenotypes including elephantiasis neuromatosa, malignant peripheral nerve sheet tumors, breast cancer, gastrointestinal stromal tumors. Conclusion: This effect on protein synthesis, rather than the type of NF1 mutation, is the key to the explanation of the genotype-phenotype correlations in the context of neurofibromatosis type 1.
KW - Elephantiasis neuromatosa; GIST; malignant peripheral nerve sheet tumors
KW - Neurofibromatosis type 1
KW - Plexiform neurofibroma; NF1 truncating mutations
UR - http://www.scopus.com/inward/record.url?scp=84906309106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906309106&partnerID=8YFLogxK
M3 - Article
C2 - 24922668
AN - SCOPUS:84906309106
SN - 0250-7005
VL - 34
SP - 3021
EP - 3030
JO - Anticancer Research
JF - Anticancer Research
IS - 6
ER -